Polarean Imaging plc is a medical-imaging technology company, revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of magnetic resonance imaging (MRI) to the respiratory healthcare community. The Company and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Company has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). It develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. Its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.